Post-Marketing Observational Study on 5% Intravenous Immunoglobulin Therapy (Alphaglobin®/Flebogamma®) in Secondary Immunodeficiency with Recurrent Serious Bacterial Infections-Reference-Cited by-同舟云学术

Post-Marketing Observational Study on 5% Intravenous Immunoglobulin Therapy (Alphaglobin®/Flebogamma®) in Secondary Immunodeficiency with Recurrent Serious Bacterial Infections

Published:2013-04 Issue: Volume: Page:n/a-n/a
ISSN:0385-5600
Container-title:Microbiology and Immunology
language:en
Short-container-title:Microbiol Immunol

Author:

Günther Georg¹,Dreger Bettina²

Affiliation:

1. Specialist for Internal Medicine; Medical Care Center for Blood and Cancer Diseases; Potsdam; Germany

2. Medical Affairs Department; Grifols Deutschland GmbH; Frankfurt; Germany

Publisher

Wiley

Subject

Virology,Immunology,Microbiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1348-0421.12060/fullpdf

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of secondary immunodeficiency in hematological malignancies: a Delphi consensus from the Middle East;Frontiers in Hematology;2024-03-08

2. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology;Critical Reviews in Oncology/Hematology;2023-01

3. Access and use of immunoglobulins in secondary supportive cancer care: A systematic literature review;The Journal of Medicine Access;2023-01

4. Impact of stopping long‐term immunoglobulin therapy in patients with secondary antibody deficiency due to haematological disease;British Journal of Haematology;2021-03-13

5. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus;European Journal of Haematology;2021-02-02